Eiko Lifesciences Ltd
Incorporated in 2021, Eiko LifeSciences
Ltd manufacturing & sells Specialty
Chemical and Fine Chemicals[1]
- Market Cap ₹ 71.1 Cr.
- Current Price ₹ 49.6
- High / Low ₹ 65.9 / 45.9
- Stock P/E 22.9
- Book Value ₹ 42.2
- Dividend Yield 0.00 %
- ROCE 3.84 %
- ROE 2.75 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 1.17 times its book value
- Promoter holding has increased by 2.74% over last quarter.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding is low: 39.9%
- Company has a low return on equity of 2.42% over last 3 years.
- Earnings include an other income of Rs.2.54 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.10 | 0.11 | 0.58 | 0.40 | 0.51 | 0.39 | -0.00 | 11.99 | 25.41 | 18.32 | 27.93 | 32.49 | 33.31 | |
| 0.09 | 0.08 | 0.47 | 0.14 | 0.18 | 0.20 | 0.17 | 11.47 | 24.10 | 17.35 | 26.31 | 30.78 | 30.67 | |
| Operating Profit | 0.01 | 0.03 | 0.11 | 0.26 | 0.33 | 0.19 | -0.17 | 0.52 | 1.31 | 0.97 | 1.62 | 1.71 | 2.64 |
| OPM % | 10.00% | 27.27% | 18.97% | 65.00% | 64.71% | 48.72% | 4.34% | 5.16% | 5.29% | 5.80% | 5.26% | 7.93% | |
| -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.43 | 0.46 | 0.67 | 0.85 | 0.18 | 1.37 | 2.54 | |
| Interest | -0.00 | -0.00 | -0.00 | 0.02 | 0.05 | 0.03 | 0.07 | 0.09 | 0.48 | 0.16 | 0.15 | 0.13 | 0.17 |
| Depreciation | -0.00 | -0.00 | -0.00 | 0.02 | 0.06 | 0.06 | 0.06 | 0.06 | 0.56 | 0.63 | 0.66 | 0.63 | 0.60 |
| Profit before tax | 0.01 | 0.03 | 0.11 | 0.22 | 0.22 | 0.10 | 0.13 | 0.83 | 0.94 | 1.03 | 0.99 | 2.32 | 4.41 |
| Tax % | -0.00% | 33.33% | 27.27% | 27.27% | 13.64% | 30.00% | -0.00% | 26.51% | 24.47% | 25.24% | 23.23% | 24.57% | |
| 0.01 | 0.02 | 0.08 | 0.17 | 0.18 | 0.07 | 0.13 | 0.61 | 0.71 | 0.77 | 0.75 | 1.74 | 3.36 | |
| EPS in Rs | 0.33 | 0.04 | 0.16 | 0.34 | 0.28 | 0.11 | 0.20 | 0.95 | 0.51 | 0.55 | 0.64 | 1.40 | 2.51 |
| Dividend Payout % | -0.00% | -0.00% | -0.00% | 44.41% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 77% |
| 5 Years: | % |
| 3 Years: | 9% |
| TTM: | -1% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 54% |
| 5 Years: | 62% |
| 3 Years: | 29% |
| TTM: | 170% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -7% |
| 3 Years: | -7% |
| 1 Year: | -1% |
| Return on Equity | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 3% |
| 3 Years: | 2% |
| Last Year: | 3% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.20 | 3.02 | 3.02 | 3.02 | 3.82 | 3.82 | 3.82 | 3.82 | 8.32 | 8.32 | 12.87 | 13.76 | 13.72 |
| Reserves | -0.00 | 0.02 | 0.10 | 0.21 | 1.73 | 1.61 | 1.66 | 8.71 | 20.31 | 21.11 | 37.81 | 42.66 | 44.21 |
| 0.02 | -0.00 | 0.25 | 0.41 | 0.37 | 0.31 | 0.26 | 1.83 | 4.63 | 0.05 | -0.00 | 1.75 | -0.00 | |
| -0.00 | 0.01 | 0.02 | 0.12 | 0.06 | 0.02 | 0.02 | 2.25 | 1.64 | 1.57 | 2.06 | 2.21 | 3.17 | |
| Total Liabilities | 0.22 | 3.05 | 3.39 | 3.76 | 5.98 | 5.76 | 5.76 | 16.61 | 34.90 | 31.05 | 52.74 | 60.38 | 61.10 |
| -0.00 | -0.00 | -0.00 | 0.49 | 0.43 | 0.37 | 0.31 | 0.25 | 14.29 | 13.88 | 13.57 | 14.26 | 13.97 | |
| CWIP | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Investments | 0.16 | 0.26 | 2.59 | 2.45 | 3.58 | 2.13 | 0.50 | 0.22 | 0.20 | 0.05 | 4.02 | 7.07 | 7.07 |
| 0.06 | 2.79 | 0.80 | 0.82 | 1.97 | 3.26 | 4.95 | 16.14 | 20.41 | 17.12 | 35.15 | 39.05 | 40.06 | |
| Total Assets | 0.22 | 3.05 | 3.39 | 3.76 | 5.98 | 5.76 | 5.76 | 16.61 | 34.90 | 31.05 | 52.74 | 60.38 | 61.10 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.01 | -0.05 | 0.19 | 0.19 | 0.24 | -0.19 | 0.77 | -0.83 | -7.73 | 4.22 | -7.08 | 2.05 | |
| -0.00 | -2.75 | 0.05 | -0.38 | -1.33 | -0.43 | -0.65 | -2.94 | 0.59 | 0.87 | -0.55 | -9.85 | |
| 0.01 | 2.80 | 0.25 | 0.15 | 1.82 | -0.08 | -0.13 | 7.81 | 3.28 | -4.70 | 20.36 | 5.97 | |
| Net Cash Flow | -0.00 | 0.01 | 0.49 | -0.04 | 0.72 | -0.71 | -0.01 | 4.05 | -3.85 | 0.40 | 12.73 | -1.83 |
| Free Cash Flow | -0.01 | -0.05 | 0.19 | -0.33 | 0.24 | -0.19 | 0.77 | -0.83 | -7.88 | 4.00 | -7.43 | 0.72 |
| CFO/OP | -100% | -133% | 191% | 96% | 85% | -84% | -459% | -125% | -574% | 427% | -435% | 137% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 109.50 | 331.82 | -0.00 | -0.00 | -0.00 | 74.87 | 103.81 | 65.50 | 141.66 | 171.59 | 113.92 | |
| Inventory Days | 2.06 | 88.26 | 20.64 | 48.70 | 50.23 | |||||||
| Days Payable | 65.30 | 21.82 | 23.82 | 19.82 | 13.87 | |||||||
| Cash Conversion Cycle | 109.50 | 331.82 | -0.00 | -0.00 | -0.00 | 74.87 | 40.57 | 131.94 | 138.48 | 200.46 | 150.28 | |
| Working Capital Days | 109.50 | 298.64 | 12.59 | 127.75 | 200.39 | 561.54 | 133.34 | 89.20 | 149.23 | 210.14 | 164.47 | |
| ROCE % | 4.88% | 1.84% | 3.43% | 6.85% | 5.65% | 2.23% | 3.48% | 9.15% | 5.88% | 3.70% | 2.84% | 3.84% |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Dec 2025 | |
|---|---|---|---|---|---|
| Number of Permanent Employees Number |
|
||||
| Manufacturing Facility Area (Badlapur) Square Meters |
|||||
| Logistics Fleet Size (TEU Containers) Units |
|||||
| SSM Formulations - Annual Capsule Capacity Crore Capsules |
|||||
| SSM Formulations - Annual Tablet Capacity Crore Tablets |
|||||
| SSM Formulations - Capsule Capacity Utilization Percentage |
|||||
| SSM Formulations - Product Manufacturing Permissions Number |
|||||
| SSM Formulations - Tablet Capacity Utilization Percentage |
|||||
Extracted by Screener AI
Documents
Announcements
-
Board Meeting Intimation for Approval Of Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Financial Year Ending On 31St March, 2026, In Accordance With Regulation 33 Of The SEBI Listing Regulation.
21 May - Board meeting on 26 May 2026 to approve audited FY2026 standalone and consolidated results; trading window closed.
-
Non Applicability Of Annual Disclosure As Per SEBI Circular - Fund Raising By Issuance Of Debt Securities By Large Corporates.
9 Apr - On 31 March 2026, Eiko Lifesciences was not a Large Corporate under SEBI debt rules.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
8 Apr - Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the quarter and year ended on 31st March, 2026 received from M/s. Bigshare …
- Closure of Trading Window 25 Mar
- Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 26 Feb
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Business Overview:[1]
ELL is in the business of manufacturing, processing, formulating, producing, buying, selling, and exporting specialty and Fine Chemicals comprising organic & inorganic chemicals, and Pharma Intermediates, etc.